The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
Oct 03, 2024•over 1 year ago
Contract Type
contract
San FranciscoHealthcare
Description
GigaGen Inc., a subsidiary of Grifols, has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNT) and a second biothreat.
Company Information
Company
GigaGen, Inc.
Location
407 CABOT ROAD
San Francisco, California, United States
About
Billions of immune cells in your bloodstream fight disease on a daily basis. GigaGen turns these cells into life-saving medical therapies.
Predictive Intelligence
Strategic
ML-powered predictions for GigaGen, Inc.'s next move
San FranciscoHealthcare